Three Firms Sign Up With MPP For Long-Acting Cabotegravir
Aurobindo, Cipla And Viatris’s Mylan Agree Deal To Produce HIV PrEP Treatment
Three generics firms – Aurobindo, Cipla and Viatris’s Mylan – have signed licensing agreements with the Medicines Patent Pool that will allow them to produce versions of ViiV Healthcare’s long-acting cabotegravir treatment for HIV pre-exposure prophylaxis.
You may also be interested in...
Medicare Weighing National Part B Coverage For ViiV’s HIV PrEP Apretude As ‘Preventive Service’
Unusual national coverage determination for a prevention-only drug was opened in response to a formal request from ViiV for its long-acting injectable.
ViiV Readies Entry To HIV PrEP Market After Apretude Approval
A long-acting injectable formulation of cabotegravir, Apretude could result in greater patient adherence to therapy, ViiV claims. The product will be priced at $3,700 per vial.
Stada Gets FDA Nod For US Epoetin Alfa Supply
Stada has received US FDA approval to supply the Retacrit epoetin alfa biosimilar to partner Pfizer for the US market, allowing it to expand on an existing European supply arrangement.